Useful AMR graphics: Poirel 2017 and Marston 2016

Dear All:

There’s a very comprehensive review of the polymyxins by Poirel, Jayol, and Nordmann just out in Clin Micro Reviews (https://journals.asm.org/doi/10.1128/CMR.00064-16). If you’re a fan of good quality graphics as way to tell the story of AMR, their Figure 4 is worth capturing! Ditto their Figure 5 of outbreaks of colistin-resistant, carbapenemase-producing K. pneumoniae. Both are shown below.

This paper also reminds me of Marson 2016 (JAMA 316:1193-204, 2016) in which the NIAID team provides two further useful graphics showing how rapidly AMR can develop and spread. Good graphics like these are so very helpful in communication!

Would all of you who are working on new products for Gram-negative rods please get really, really, REALLY busy?

Best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx


Figures 4 and 5 from Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev. 2017;30(2):557-96.

Picture

Picture

Below left: Time (years) to resistance for new classes. Below right: Recovery of mcr-1-expressing E’bacteriaceae. From Marston HD et al. Antimicrobial Resistance. JAMA. 2016;316(11):1193-204.

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top